

# Ann W McMahon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8434381/publications.pdf>

Version: 2024-02-01

13  
papers

715  
citations

1040056

9  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

854  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outbreak of Adverse Reactions Associated with Contaminated Heparin. <i>New England Journal of Medicine</i> , 2008, 359, 2674-2684.	27.0	258
2	Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. <i>Vaccine</i> , 2007, 25, 1727-1734.	3.8	114
3	Age and Risks of FDA-Approved Long-Acting Î²2-Adrenergic Receptor Agonists. <i>Pediatrics</i> , 2011, 128, e1147-e1154.	2.1	74
4	Adverse Events After Inactivated Influenza Vaccination Among Children Less Than 2 Years of Age: Analysis of Reports From the Vaccine Adverse Event Reporting System, 1990-2003. <i>Pediatrics</i> , 2005, 115, 453-460.	2.1	62
5	Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 921-933.	1.9	54
6	Octreotide use and safety in infants with hyperinsulinism. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 26-31.	1.9	46
7	Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6â€“23 months of age. <i>Vaccine</i> , 2009, 27, 4278-4283.	3.8	36
8	Safety of octreotide in hospitalized infants. <i>Early Human Development</i> , 2015, 91, 387-392.	1.8	28
9	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. <i>Drugs - Real World Outcomes</i> , 2020, 7, 97-107.	1.6	15
10	Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review. <i>Paediatric Drugs</i> , 2019, 21, 47-58.	3.1	12
11	Pediatric post-marketing safety systems in North America: assessment of the current status. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 785-792.	1.9	11
12	Stratification, Hypothesis Testing, and Clinical Trial Simulation in Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 817-822.	1.6	4
13	Workshop on evaluation of pediatric longâ€“term neurocognitive development and medical products. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1428-1430.	1.9	1